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Ann Arbor, Michigan; and New Orleans, LouisianaObjectives This study sought to characterize usage and outcomes of carotid stenting platforms.
Background A variety of stents and embolic protection devices (EPDs) are used for carotid artery
stenting. Little is known about current usage patterns and differences in outcomes with these devices.
Methods We analyzed 12,135 consecutive carotid stent procedures in the NCDR (National
Cardiovascular Data Registry) CARE (Carotid Artery Revascularization and Endarterectomy) registry
performed between January 1, 2007 and March 31, 2012. We compared baseline characteristics and
crude and multivariable-adjusted rates of in-hospital combined death/stroke among patients treated
with Acculink/Accunet (Abbott Laboratories, Abbott Park, Illinois), Xact/Emboshield (Abbott), and
Precise/Angioguard (Cordis Corporation, Bridgewater, New Jersey) stent/EPD combinations.
Results In 78.2% of cases, stents were used in conjunction with their speciﬁc, corresponding
U.S. Food and Drug Administration–approved EPD. The Acculink/Accunet (n ¼ 2,617, 21.6%),
Xact/Emboshield (n ¼ 3,507, 28.9%), and Precise/Angioguard (n ¼ 2,696, 22.2%) stent/EPD
combinations were used in 72.7% of all cases. The Protégé/SpiderFx (ev3 Endovascular Inc., Plymouth,
Minnesota) (n ¼ 453, 3.7%) and Wallstent/Filterwire (Boston Scientiﬁc, Natick, Massachusetts) (n ¼ 213,
1.8%) devices were used in a minority of cases. In unadjusted analyses, the Precise/Angioguard system
was associated with higher rates of the primary outcome than were the Acculink/Accunet (2.5% vs.
1.8%; p ¼ 0.058) and Xact/Emboshield (2.5% vs. 1.9%; p ¼ 0.14) systems that were not statistically
different. In adjusted analyses, differences between Precise/Angioguard and Accunet/Acculink
(odds ratio [OR]: 1.48, 95% conﬁdence interval [CI]: 0.89 to 2.47; p ¼ 0.065), Precise/Angioguard and
Xact/Emboshield (OR: 1.16, 95% CI: 0.77 to 1.76; p ¼ 0.38), and Xact/Emboshield and Accunet/Acculink
(OR: 1.28, 95% CI: 0.82 to 1.97; p ¼ 0.18) remained nonsigniﬁcant.
Conclusions In modern U.S. practice, the Acculink/Accunet, Xact/Emboshield, and Precise/
Angioguard carotid stenting systems are used in most cases and are associated with similarly low rates
of adverse events. (J Am Coll Cardiol Intv 2014;7:171–7) ª 2014 by the American College of
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172Carotid artery stenting (CAS) is a commonly used revas-
cularization procedure to reduce the risk of stroke among
patients with asymptomatic or symptomatic carotid stenosis.
In the United States, nearly all procedures are performed
with the use of embolic protection devices (EPDs), and
EPD use is required for Center for Medicare and Medicaid
Services reimbursement in cases of elective stenting (1).
Operators may choose from multiple U.S. Food and Drug
Administration (FDA)–approved and investigational stents
and EPDs. A variety of factors may inﬂuence the choice of
stent and EPD, including device availability, clinical trial
or post-marketing registry participation, stent geometrySee page 178considerations (i.e., open- vs. closed-cell structure or tapered
vs. nontapered design), and speciﬁc EPD characteristics.
Little is known about current U.S. usage patterns of the
various carotid stents and EPDs. The CARE (Carotid
Artery Revascularization and Endarterectomy) registry
provides a unique opportunity to analyze contemporaryCorp. Dr. Aronow is an unpaid consu
the Steering Committee Chair for
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Administration
OR = odds ratiousage patterns as well as the
comparative effectiveness of
the most commonly used carotid
stenting/EPD systems.Methods
The CARE registry is a national
registry enrolling patients with
carotid stenosis who have un-
dergone revascularization witheither carotid endarterectomy or CAS. It was created to
monitor clinical practice, assess patient outcomes, and pro-
vide a framework for quality improvement initiatives (2). As
of November 2012, the registry included 14,343 CAS pro-
cedures performed at 174 hospitals. The current research
was supported by the American College of Cardiology
Foundation’s NCDR (National Cardiovascular Data
Registry).
All patients undergoing CAS from January 2007 through
March 2012 were initially evaluated for inclusion in this
analysis. Patients with acute evolving stroke (n ¼ 367,
2.7%), with spontaneous carotid artery dissection (n ¼ 124,
0.9%), or undergoing general anesthesia (n ¼ 543, 4.1%)
were excluded from analysis, as these patients represented altant for Silk Road Medical, Inc. Dr. White is
the NCDR CARE registry; he accepts no
Rosenﬁeld has received research grants from
eral Vascular, IDEV, Cordis, and Atrium; has
s from Abbott Vascular, VORTEX/AngioDy-
gement, and Becker Ventures; has equity in
rd (Cordis), and Micell; and serves on the boarddistinct subgroup of patients with substantially higher pro-
cedural risk that were likely nonelective cases. Patients who
received proximal embolic protection (n ¼ 305, 2.42%) or
distal occlusion balloon (n ¼ 24, 0.19%) were excluded from
this analysis due to the very low usage rates of these devices
during the period analyzed. The primary outcome of interest
was the occurrence of in-hospital major adverse events,
deﬁned as the composite of stroke and all-cause death.
Stroke was deﬁned as a new neurologic deﬁcit persisting for
more than 24 h.
For each patient, information on demographics, comorbid
conditions, cardiac history, neurologic history, neurologic
risk factors, anatomical and procedural information, and
lesion characteristics were collected. Demographics and
other general descriptive variables included age, sex, body
mass index, and ethnicity. Comorbid conditions assessed
included the following: hypertension, diabetes, renal insuf-
ﬁciency (glomerular ﬁltration rate <60 ml/min), dyslipide-
mia, peripheral artery disease, chronic lung disease, smoking
status, major surgery planned within 8 weeks, previous neck
irradiation, and previous neck surgery. Cardiac history var-
iables included ischemic heart disease, history of heart fail-
ure, and history of atrial ﬁbrillation/ﬂutter. Neurologic
variables assessed included the following: dementia, seizure
disorders, previous ipsilateral carotid endarterectomy, pre-
vious ipsilateral CAS, previous transient ischemic attack,
previous ischemic stroke, and pre-procedure National In-
stitutes of Health stroke scale. Site-reported anatomical and
procedural variables included the following: target vessel,
need for urgent cardiac surgery within 30 days, symptomatic
for target lesion within 6 months, contralateral carotid artery
occlusion, and aortic arch type. Lesion characteristics
assessed included the following: presence of visible
thrombus, dense calciﬁcation, target lesion location, lesion
length, minimal luminal diameter, and pre-procedure ste-
nosis severity. Carotid artery restenosis was deﬁned as >50%
diameter stenosis at or adjacent to the site previously treated
with balloon angioplasty or stent.
Statistical analysis. An initial cross match was performed of
stent type and distal ﬁlter EPD type. Baseline comparisons
and unadjusted analyses of patients undergoing CAS using
different stent/EPD combinations were performed using
chi-square tests for categorical variables and t tests for
continuous variables. We then conducted pairwise compari-
sons of adjusted rates of stroke or death using a logistic
regression. For these comparisons, we adjusted for the pre-
dicted risk of in-hospital stroke or death using a validatedof directors for VIVA Physicians (501c3). Dr. Yeh has received institutional research
support for and is an investigator at the Harvard Clinical Research Institute. All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose. Sotirios Tsimikas, MD, served as Guest Editor for this paper.
Manuscript received August 9, 2013; revised manuscript received September 25, 2013,
accepted October 4, 2013.
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173CAS risk score that incorporated the following variables:
impending major surgery, previous stroke, age, sympto-
matic lesion, atrial ﬁbrillation, and absence of previous ipsi-
lateral carotid endarterectomy (3).Additional analyses included
an adjusted analysis of 30-day event rates for the portion of the
cohort in whom this was available and a test for interaction of
symptomatic/asymptomatic status with our comparison of
device types. All analyses were conducted using SAS (version
9.2, SAS Institute, Cary, North Carolina).
Results
The Acculink/Accunet (Abbott Laboratories, Abbott Park,
Illinois) (n ¼ 2,617, 21.6%), Xact/Emboshield (Abbott)
(n ¼ 3,507, 28.9%), and Precise/Angioguard (Cordis Cor-
poration, Bridgewater, New Jersey) (n ¼ 2,696, 22.2%)
stent/EPD combinations were used in 72.7% of all cases;
the Protégé/SpiderFx (ev3 Endovascular Inc., Plymouth,
Minnesota) (n ¼ 453, 3.73%) and Wallstent/Filterwire
(Boston Scientiﬁc, Natick, Massachusetts) (n ¼ 213, 1.76%)
devices were used in fewer cases. In 78.2% of cases, stents
were used in conjunction with their speciﬁc, corresponding
FDA-approved EPD (Fig. 1). Baseline characteristics of the
patients receiving the 3 most commonly used carotid stent
systems are listed in Table 1.
In unadjusted analyses, the Precise/Angioguard system
was associated with higher rates of the primary outcome
than the Acculink/Accunet (2.5% vs. 1.8%; p ¼ 0.058) and
Xact/Emboshield (2.5% vs. 1.9%; p ¼ 0.14) systems,Figure 1. Carotid Stent Device Usage
Percentage usage of various carotid stent/embolic protection device combinations in
In 78.2% of cases, stents were used in conjunction with their speciﬁc, correspondingalthough neither comparison met statistical signiﬁcance.
There was no difference in the primary outcome between the
Acculink/Accunet and Xact/Emboshield systems (1.8% vs.
1.9%; p ¼ 0.63). The Precise/Angioguard system was
associated with a signiﬁcantly higher rate of stroke than
was the Xact/Emboshield system (2.3% vs. 1.7%; p ¼ 0.02)
and with a nonsigniﬁcant trend toward a higher stroke rate
than the Accunet/Acculink system (2.3% vs. 1.6%; p ¼
0.06). There was no difference in the stroke rate between the
Accunet/Acculink and Xact/Emboshield systems (1.6% vs.
1.7%; p ¼ 0.84). Unadjusted outcomes are shown in
Table 2.
In adjusted analyses, differences in the primary outcome
between Precise/Angioguard and Accunet/Acculink (odds
ratio [OR]: 1.48, 95% conﬁdence interval [CI]: 0.89 to 2.47;
p ¼ 0.065), Precise/Angioguard and Xact/Emboshield
(OR: 1.16, 95% CI: 0.77 to 1.76; p ¼ 0.38), as well as those
between Xact/Emboshield and Accunet/Acculink (OR:
1.28, 95% CI: 0.82 to 1.97; p ¼ 0.18) were not signiﬁcant
(Fig. 2). A test for interaction of symptomatic/asymptomatic
status with our comparison of device types was negative
(p value for interaction ¼ 0.76).
An additional secondary analysis was performed on pati-
ents in whom 30-day outcome data was available, which
was 78% of the total cohort (Table 3). This demonstrated
similar results to the primary in-hospital event analysis
with a trend toward increased stroke/death with use of
Angioguard/Precise that did not meet statistical signiﬁ-
cance after adjustment.12,145 consecutive U.S. cases performed between January 2007 and March 2012.
U.S. Food and Drug Administration–approved embolic protection device.






(n ¼ 3,507) p Value
Demographics
Age, yrs 71.2  10.0 71.1  10.6 70.1  9.9 <0.001
Sex 0.914
Male 1,637 (62.6) 1,693 (62.8) 2,184 (62.3)
Female 980 (37.4) 1,003 (37.2) 1,323 (37.7)
Body mass index, kg/m2 28.9  10.4 29.2  16.9 28.9  11.7 0.568
Caucasian 2,420 (92.5) 2,510 (93.1) 3,241 (92.4) 0.547
GFR <60 ml/min 972 (38.1) 1,061 (40.5) 1,287 (37.7) 0.071
Smoker 1,930 (73.7) 1,976 (73.3) 2,598 (74.1) 0.784
Hypertension 2,333 (89.2) 2,482 (92.1) 3,209 (91.5) <0.001
Dyslipidemia 2,274 (86.9) 2,400 (89.0) 3,103 (88.5) 0.043
Peripheral arterial disease 1,084 (41.4) 1,138 (42.2) 1,559 (44.5) 0.044
Diabetes mellitus 990 (37.8) 1,001 (37.1) 1,389 (39.6) 0.114
Chronic lung disease 711 (27.2) 787 (29.2) 964 (27.5) 0.203
Impending major surgery 98 (3.7) 100 (3.7) 120 (3.4) 0.753
Previous neck radiation 159 (6.1) 159 (5.9) 182 (5.2) 0.274
Previous neck surgery 173 (6.6) 157 (5.8) 181 (5.2) 0.056
Cardiac history
Ischemic heart disease 1,610 (61.5) 1,505 (55.8) 1,840 (52.5) <0.001
Heart failure 455 (17.4) 466 (17.3) 618 (17.6) 0.934
Atrial ﬁbrillation or ﬂutter 300 (11.5) 384 (14.3) 427 (12.2) 0.006
Neurologic history and risk factors pre-procedure
Dementia or Alzheimer’s disease 75 (2.9) 93 (3.4) 108 (3.1) 0.463
Prior TIA 791 (30.2) 827 (30.7) 1,042 (29.7) 0.712
Prior ischemic stroke 384 (14.7) 408 (15.1) 442 (12.6) 0.008
Pre-procedure NIH stroke scale total score 0.7  2.0 0.7  2.0 0.7  2.1 0.628
Procedure information
Target carotid vessel, right 1,288 (49.2) 1,335 (49.5) 1,745 (49.8) 0.916
Urgent cardiac surgery within 30 days 68 (2.8) 94 (3.6) 126 (3.7) 0.131
Target lesion symptomatic within past 6 months 979 (37.4) 1,055 (39.1) 1,279 (36.5) 0.104
Restenosis in target vessel after previous CAS 69 (2.6) 51 (1.9) 93 (2.7) 0.105
Restenosis in target vessel after previous CEA 386 (14.7) 500 (18.5) 421 (12.0) <0.001
Contralateral carotid artery occlusion 273 (10.4) 283 (10.5) 352 (10.0) 0.807
Aortic arch type 0.667
Type I 1,227 (49.9) 1,335 (51.8) 1,722 (51.8)
Type II 966 (39.3) 972 (37.7) 1,255 (37.7)
Type III 264 (10.7) 272 (10.5) 350 (10.5)
Pre-dilation prior to EPD 282 (10.8) 206 (7.7) 322 (9.2) <0.001
Pre-dilation prior to attempted stent implant 2,052 (79.1) 1,952 (73.0) 2,651 (76.0) <0.001
Post-dilation performed 2,432 (93.0) 2,402 (89.1) 3,239 (92.4) <0.001
Continued on the next page
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174Discussion
Our analysis revealed that, in the great majority of cases,
carotid stents are used with their matched FDA-approved
EPD. Several factors may inﬂuence this pattern of use.
First, the FDA approves carotid stenting systems as a unit
of stent and EPD. Operators may be more comfortable
using an FDA-approved unit rather than “mixing and
matching” stents with other EPDs. Additionally, reim-
bursement restrictions from the Center for Medicare andMedicaid Services likely have a large impact on this usage
pattern. Currently, despite FDA approvals, Medicare re-
imburses patients with asymptomatic severe carotid stenosis
for CAS only if they are enrolled in a pre-approval or
post-marketing surveillance study. Clinical trials and post-
marketing surveillance studies are sponsored by medical
device companies that require use of a speciﬁc paired stent/
EPD combination. The availability of such studies may
greatly inﬂuence observed patterns of U.S. carotid stent/







(n ¼ 3,507) p Value
Lesion
Visible thrombus present 64 (2.5) 86 (3.2) 127 (3.7%) 0.031
Dense calciﬁcation 314 (12.0) 388 (14.4) 470 (13.4) 0.036
Target lesion location <0.001
Isolated CCA 182 (7.0) 240 (8.9) 211 (6.0)
Isolated ICA 1,974 (75.5) 1,898 (70.5) 2,454 (70.2)
Bifurcation 460 (17.6) 556 (20.6) 831 (23.8)
Lesion length, mm 21.1  10.0 18.3  9.5 20.1  9.3 <0.001
Pre-procedure stenosis percentage 84.2  10.3 84.4  10.5 84.6  10.5 0.446
Ulceration 672 (25.9) 828 (30.8) 1,060 (30.6) <0.001
Minimal luminal diameter 2.0  2.2 1.8  2.0 1.5  1.7 <0.001
Successful EPD placement 2,584 (98.7) 2,674 (99.2) 3,484 (99.3) 0.039
Values are mean  SD or n (%).
CAS ¼ carotid artery stenting; CCA ¼ common carotid artery; CEA ¼ carotid endarterectomy; EPD ¼ embolic protection device; GFR ¼
glomerular ﬁltration rate; ICA ¼ internal carotid artery; NIH ¼ National Institutes of Health; TIA ¼ transient ischemic attack.
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175and Xact stents may decrease following closure of the
CHOICE [Carotid Stenting For High Surgical-Risk Pati-
ents; Evaluating Outcomes Through The Collection Of
Clinical Evidence] post-marketing study, whereas those
for Precise stents may increase given continuation of the
SAPPHIRE [Stenting and Angioplasty With Protection
in Patients at High Risk for Endarterectomy] WW
[Worldwide] post-marketing study). It is possible that a
strategy of selecting carotid stents and EPD individually
according to procedural characteristics might beneﬁt oper-
ators and patients. The current usage pattern is analogous to
a situation in which coronary interventional operators could
only use a single wire with a matching stent as opposed to
choosing stents and wires independently of one another,
each optimally suited for the particular anatomical situation
encountered.
To our knowledge, this is the ﬁrst large-scale assessment
of carotid stenting device usage patterns. We sought to
compare devices against one another in the fashion in which
they are used in real-world clinical practice. Previous ana-
lyses of carotid stents have been smaller in scope and have
grouped patients according to other designations such as
open-/closed-cell stent type. Open-cell stents provide more





In-hospital death/stroke 46 (1.8)
In-hospital mortality 8 (0.3)
In-hospital stroke 42 (1.6)
Values are n (%).area. In contrast, closed-cell stents are more rigid, which
may prove unfavorable for delivery and deployment in
vessels with signiﬁcant tortuosity, but may more completely
cover carotid plaque.
Data regarding open- versus closed-cell stents has been
mixed. Two previous analyses have suggested a beneﬁt of
closed-cell stents that may be more pronounced in patients
with symptomatic lesions (4,5). In contrast, Schillinger et al.
(6) analyzed a registry including 1,684 carotid stenting
cases from 10 European centers and found no signiﬁcant
differences in adverse event rates between patients treated
with open- and closed-cell stents. More recently, a small
randomized trial showed no difference in transcranial
Doppler-detected microembolization rates between the 2
stent types (7).
Traditionally, stents with free cell areas<5 mm2 have been
classiﬁed as closed-cell, which is admittedly a somewhat
arbitrary cutoff. The Xact stent has a free cell area of 2.74
mm2, and the Precise stent has a free cell area of 5.89 mm2.
The Acculink stent has the largest free cell area of any
currently available carotid stent at 11.48 mm2 (8). In the
>9,000 patients analyzed in our study, outcomes were not
statistically different between patients treated with each of




(n ¼ 3,507) p Value
68 (2.5) 68 (1.9) 0.12
10 (0.4) 13 (0.4) 0.89
63 (2.3) 58 (1.7) 0.08
Figure 2. Adjusted HRs for In-Hospital Death or Stroke Comparing 3 Carotid Stenting Systems
Pairwise comparisons among the 3 most commonly used carotid stenting systems in the United States adjusted for the predicted risk of in-hospital stroke or death
using a validated coronary artery stenting risk score. Hazard ratios (HRs) are depicted by solid circles, with 95% conﬁdence intervals (CIs) shown as lines on either side
of these points. There were no statistically signiﬁcant differences in stroke and death among the 3 systems.
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176cell areas, when the stent platformwas used in concert with its
respective EPD. This ﬁnding should provide support for
operators to use their judgment to select the stent most
favorable for a particular anatomic or clinical situation.
The various EPDs also possess unique technical charac-
teristics that have been postulated to affect the outcomes
of carotid stenting. There are several distal ﬁlter EPDs
currently available, and they exhibit variability in pore size,
crossing proﬁle, and ﬁlter diameter. In addition, some EPDs
feature a concentric design, in which the guidewire passes
directly through the middle of the ﬁlter. Others possess an
eccentric design, with a guidewire attached to an edge of
the ﬁlter off the central axis.
Several previous analyses of EPDs have been performed.
An analysis by Zahn et al. (9) revealed distal ﬁlter EPDs to
be equally effective at preventing adverse events as a distal
occlusion balloon. We observed in our current analysis of





30-day death/stroke 63 (3.2) 103 (4.5)
30-day mortality 15 (0.8) 19 (0.8)
30-day stroke 53 (2.7) 90 (3.9)
Values are n (%).never used in contemporary U.S. practice. Indeed, the Per-
cuSurge GuardWire (Medtronic, Minneapolis, Minnesota)
distal occlusion balloon is no longer clinically available in the
United States. Previous studies of eccentric versus concentric
ﬁlter designs have been limited in size or confounded by se-
lection bias (4,10). The 3 EPDs that we evaluated all have
concentric design with mild variance in pore size and crossing
proﬁles. No signiﬁcant differences were seen in outcomeswith
use of these devices in concert with their matching stents.
Our study has several strengths. In contrast to existing
data, our analysis represents a modern U.S. experience. We
have clariﬁed usage patterns across a wide range of patient,
institutional, and operator characteristics. Our study also
represents the largest comparative analysis performed of
patients undergoing CAS. Previous analyses have included
less data and grouped patients according to designations
such as open-/closed-cell stent type and distal balloon
versus ﬁlter embolic protection. These comparativerotid Stenting System
ise Emboshield/Xact
(n ¼ 2,598) p Value Adjusted p Value
88 (3.4) 0.044 0.114
16 (0.6) 0.67 0.812
76 (2.9) 0.043 0.140
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177designations do not have as much relevance to contemporary
practice given the previously mentioned usage patterns.
Study limitations. First, we were not able to assess separately
outcome effects that could be individually associated with
either a stent or an EPD. In nearly 80% of cases, stents were
used with their matched FDA-approved EPDs. This pre-
cluded separate analysis of these 2 variables. It should be
noted that this is an important confounder of previous
comparative analyses of stents and EPDs. As the CARE
registry currently has complete data available only for in-
hospital outcomes, we cannot exclude the possibility of
signiﬁcant differences in either intermediate- or long-term
outcomes, including restenosis rates between the stents/
EPDs we compared. However, nearly 80% of our cohort
had 30-day adverse event data available, and these results
mirrored our in-hospital outcomes. We also cannot exclude
the possibility of differences in outcome with eccentric
versus concentric EPDs as all 3 of our analyzed EPDs have
a concentric design; given the low event rates across
our 3 groups, though, it is unlikely that eccentric distal
ﬁlter EPDs would have a signiﬁcantly positive impact on
event rates. Nearly three-quarters of our patients had post-
procedure National Institutes of Health stroke scales per-
formed and recorded by certiﬁed personnel. The fact that
independent neurologic assessment did not exist for every
patient in this registry is in keeping with the experience in
published and ongoing randomized trials of carotid artery
stenting. Speciﬁc noninvasive imaging lesion characteristics
that may be associated with a higher risk of stroke such as
“hypoechoic plaque” and “intraplaque hemorrhage” were not
available for analysis. Variability in carotid stenting tech-
nique, including the use of pre- and post-dilation, represents
an additional potential confounder. Also, it is possible that a
statistically signiﬁcant difference in the primary outcome
between the stent/EPD systems would emerge with analysis
of several thousand additional cases. However, given the
small absolute differences in adverse event rates seen in this
study (<1%), such a difference is unlikely to have strong
clinical relevance. Despite our assessment of 35 clinical
variables, we also cannot exclude the possibility of unmea-
sured confounders inﬂuencing our analysis.
Conclusions
Overall, our analysis demonstrates that carotid stenting
for symptomatic and asymptomatic disease is being per-
formed with low adverse event rates across a wide range of
institutions domestically using 3 particular stent/EPDsystems. Periprocedural stroke prevention remains the most
important goal in new technology evaluation for carotid
stenosis. Our study suggests that a continued focus on stent
and distal ﬁlter EPD characteristics is not likely to lead to
dramatically improved event rates, and efforts at periproce-
dural stroke reduction can focus elsewhere. Given the known
learning curve associated with carotid stenting, operator
comfort with individual stenting systems and with case
selection is likely of more import in reducing event rates
than are technical differences between devices (11).
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